Pulmonx Corp
Qualité des données : 100%
LUNG
Nasdaq
Manufacturing
Measuring & Analyzing Instruments
1,37 €
▲
0,01 €
(0,74%)
Cap. Boursière: 57,86 M
Prix
1,37 €
Cap. Boursière
57,86 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—
Quick Summary
Points Clés
Revenue grew 16,93% annually over 5 years — strong growth
Negative free cash flow of -32,83 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 8,92%
Capital efficient — spends only 0,50% of revenue on capex
Croissance
Revenue Growth (5Y)
16,93%
Au-dessus de la moyenne du secteur (1,82%)
Revenue (1Y)8,01%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Qualité
Return on Equity
-83,65%
En dessous de la moyenne du secteur (-53,53%)
ROIC-35,28%
Net Margin-59,67%
Op. Margin-59,30%
Sécurité
Debt / Equity
0,62
Au-dessus de la moyenne du secteur (0,31)
Current Ratio4,86
Interest Coverage-17,01
Valorisation
PE (TTM|NTM)
-1,07 | -1,36
Au-dessus de la moyenne du secteur (-1,48)
P/B Ratio0,96
EV/EBITDAN/A
Dividend YieldN/A
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1366 pairs)
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1366 pairs)| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | -1,1 | -1,5 |
| P/B | 1,0 | 1,6 |
| ROE % | -83,7 | -53,5 |
| Net Margin % | -59,7 | -41,5 |
| Rev Growth 5Y % | 16,9 | 1,8 |
| D/E | 0,6 | 0,3 |
Objectif de Cours des Analystes
6 analystes
Buy
Actuel
1,37 €
Objectif
5,17 €
2,50 €
3,50 €
14,00 €
Prévisions
P/E Prévisionnel
-1,36
BPA Prévisionnel
-1,01 €
CA Est.
107,71 M
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2027 |
-1,01 €
-1,13 € – -0,89 €
|
107,71 M | 5 |
| FY2026 |
-1,14 €
-1,17 € – -1,11 €
|
90,87 M | 6 |
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| 2026 Q2 |
-0,28 €
-0,29 € – -0,27 €
|
22,42 M | 6 |
| 2026 Q1 |
-0,33 €
-0,34 € – -0,30 €
|
20,43 M | 6 |
Surprises de Résultats
Derniers 4 trimestres
| Trimestre | BPA Est. | BPA Réel | Surprise |
|---|---|---|---|
| Q42025 | -0,39 € | -0,25 € | +35,1% |
| Q32025 | -0,42 € | -0,34 € | +18,7% |
| Q22025 | -0,40 € | -0,38 € | +5,4% |
| Q12025 | -0,40 € | -0,36 € | +10,0% |
ETFs Holding This Stock
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 8,01% | Revenue Growth (3Y) | 14,79% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 16,93% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 90,50 M | Net Income (TTM) | -54,00 M |
| ROE | -83,65% | ROA | -37,83% |
| Gross Margin | 74,19% | Operating Margin | -59,30% |
| Net Margin | -59,67% | Free Cash Flow (TTM) | -32,83 M |
| ROIC | -35,28% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,62 | Current Ratio | 4,86 |
| Interest Coverage | -17,01 | Asset Turnover | 0,63 |
| Working Capital | 88,36 M | Tangible Book Value | 57,70 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1,07 | Forward P/E | -1,36 |
| P/B Ratio | 0,96 | P/S Ratio | 0,64 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 0,54 | Fwd Earnings Yield | N/A |
| FCF Yield | -56,73% | ||
| Market Cap | 57,86 M | Enterprise Value | 18,55 M |
| Per Share | |||
| EPS (Diluted TTM) | -1,33 | Revenue / Share | 2,14 |
| FCF / Share | -0,78 | OCF / Share | -0,77 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 0,50% | FCF Conversion | 60,79% |
| SBC-Adj. FCF | -55,66 M | Growth Momentum | -8,92 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 90,50 M | 83,79 M | 68,68 M | 53,66 M | 48,42 M |
| Net Income | -54,00 M | -56,39 M | -60,84 M | -58,92 M | -48,66 M |
| EPS (Diluted) | -1,33 | -1,44 | -1,60 | -1,59 | -1,35 |
| Gross Profit | 67,14 M | 62,00 M | 50,75 M | 39,87 M | 35,63 M |
| Operating Income | -53,66 M | -57,70 M | -61,94 M | -58,64 M | -47,30 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 19,49 M | 17,57 M | 18,08 M | 15,40 M | 13,06 M |
| SG&A Expenses | 101,31 M | 102,14 M | 94,61 M | 83,11 M | 69,87 M |
| D&A | — | — | — | — | — |
| Interest Expense | 3,16 M | 3,51 M | 3,23 M | 1,07 M | 829 000,0 |
| Income Tax | 626 000,0 | 500 000,0 | 571 000,0 | 353 000,0 | 343 000,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 129,29 M | 162,85 M | 177,78 M | 193,68 M | 235,17 M |
| Total Liabilities | 75,18 M | 77,04 M | 59,47 M | 39,67 M | 41,93 M |
| Shareholders' Equity | 54,12 M | 85,81 M | 118,32 M | 154,01 M | 193,24 M |
| Total Debt | 37,20 M | 40,35 M | 39,40 M | 17,32 M | 17,42 M |
| Cash & Equivalents | 69,75 M | 70,91 M | 83,55 M | 101,74 M | 148,48 M |
| Current Assets | 101,68 M | 136,25 M | 150,42 M | 168,95 M | 208,00 M |
| Current Liabilities | 20,06 M | 24,44 M | 23,16 M | 18,49 M | 17,55 M |
{"event":"ticker_viewed","properties":{"ticker":"LUNG","listing_kind":"stock","pathname":"/stocks/lung","exchange":"Nasdaq","country":"US"}}
